Abstract
The article presents the results of an innovative experimental study of pharmacotherapy of systemic autoimmune diseases in a pandemic of coronavirus infection is a timely and socially oriented way. The methodology of conducting a content analysis based on the theoretical principles of pharmaceutical and medical law and its components. Author used the method of drug selection developed by the Department of Medical and Pharmaceutical Law, General and Clinical Pharmacy of the Kharkiv Medical Academy of Postgraduate Education. Content analysis was performed by dosage forms by grouping them using the Sturgess formula, followed by the construction of discrete series of variations and distribution polygon. Received data made possible to state, that in some circumstances, doctors have a choice of both drugs and dosage forms. However, the data obtained show a lack of balance between supply and demand for patients and physicians. The analysis allows to obtain a complete description of the balance of "supply and demand" between the range and types of dosage forms of drugs INN Silymarin ATC code A05BA03, that approved for use.
Highlights
In the current context of the spread of the coronavirus pandemic, the role of innovative methods in the study of pharmacotherapy of systemic diseases among patients with dual health disorders is growing
The methodology of conducting a content analysis of drugs according to International nonproprietary name (INN) Silymarin ATC code A05BA03 was based on the theoretical principles of pharmaceutical and medical law and its components: pharmaceutical and medical legislation; forensic pharmacy in the framework of forensic and pharmaceutical practice; evidence-based medicine and evidence-based pharmacy; clinical pharmacology and pharmacotherapy [12, 13, 14, 15, 16]
An innovative experimental study is that the content analysis based on the creation of a neutral framework for the classification of efficacy descriptions drugs of the INN Silymarin ATC code A05BA03
Summary
In the current context of the spread of the coronavirus pandemic, the role of innovative methods in the study of pharmacotherapy of systemic diseases among patients with dual health disorders is growing. Pharmacotherapy of patients with systemic autoimmune diseases during the COVID-19 pandemic is a topical issue. Further analysis of COVID-19 among patients with systemic autoimmune diseases is important [1, 2, 3]. Today it is important to use modern, effective and safe drugs for pharmacotherapy of systemic autoimmune diseases, which are selected on the principles of evidence-based medicine, forensic pharmacy, evidence-based pharmacy, medical and pharmaceutical law [4, 5, 6, 7, 8, 9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
